PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
24.38%
Revenue growth at 50-75% of ENPH's 48.37%. Martin Whitman would worry about competitiveness or product relevance.
102.35%
Gross profit growth above 1.5x ENPH's 28.38%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
186.59%
EBIT growth above 1.5x ENPH's 52.85%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
1259.49%
Operating income growth above 1.5x ENPH's 52.85%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
824.29%
Net income growth above 1.5x ENPH's 85.44%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
830.77%
EPS growth above 1.5x ENPH's 83.87%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
766.67%
Diluted EPS growth above 1.5x ENPH's 78.57%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.09%
Share reduction more than 1.5x ENPH's 0.69%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.81%
Diluted share reduction more than 1.5x ENPH's 2.94%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
134.63%
OCF growth above 1.5x ENPH's 24.71%. David Dodd would confirm a clear edge in underlying cash generation.
125.80%
FCF growth above 1.5x ENPH's 18.45%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-79.51%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-27.17%
Negative 5Y CAGR while ENPH stands at 43.78%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-57.44%
Negative 3Y CAGR while ENPH stands at 124.31%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-96.52%
Negative 10Y OCF/share CAGR while ENPH stands at 113.54%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
104.06%
Below 50% of ENPH's 268.05%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-74.13%
Negative 3Y OCF/share CAGR while ENPH stands at 3067.95%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
52.21%
Below 50% of ENPH's 109.25%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
357.82%
5Y net income/share CAGR 1.25-1.5x ENPH's 264.77%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
159.44%
Below 50% of ENPH's 1775.37%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-86.30%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-77.75%
Negative 5Y equity/share growth while ENPH is at 316.03%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
131.73%
Below 50% of ENPH's 3678.89%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while ENPH invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-12.53%
Firm’s AR is declining while ENPH shows 48.84%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
18.21%
Inventory growth well above ENPH's 11.27%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
13.60%
Asset growth 1.25-1.5x ENPH's 9.87%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
5847.50%
BV/share growth above 1.5x ENPH's 15.49%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-26.60%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-38.72%
Our R&D shrinks while ENPH invests at 4.98%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
48.07%
We expand SG&A while ENPH cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.